CytomX Therapeutics (CTMX) Intangibles (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Intangibles came in at $401000.0 in Q1 2026, down 26.69% YoY from $547000.0 in Q1 2025, and down 8.45% on a QoQ basis from $438000.0 in Q4 2025.
CytomX Therapeutics (CTMX) Intangibles (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Intangibles data on file, last reported at $401000.0 in Q1 2026.
- Quarterly Intangibles fell 26.69% year-over-year to $401000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $401000.0 (down 26.69% YoY) and the FY2025 annual result came in at $438000.0, down 24.87% from the prior year.
- Intangibles fell to $401000.0 in Q1 2026, from $438000.0 in the prior quarter.
- In the past five years, Intangibles ranged from a high of $984000.0 in Q1 2022 to a low of $401000.0 in Q1 2026.
- A 5-year average of $692705.9 and a median of $693000.0 in 2024 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2022 — Intangibles declined 12.92% — and 2026, when it decreased 26.69%.
- Tracing CTMX's Intangibles over 5 years: stood at $875000.0 in 2022, then dropped by 16.69% to $729000.0 in 2023, then fell by 20.03% to $583000.0 in 2024, then retreated by 24.87% to $438000.0 in 2025, then slipped by 8.45% to $401000.0 in 2026.
- The last three Intangibles figures came in at $401000.0 (Q1 2026), $438000.0 (Q4 2025), and $474000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 365,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 365,000.00 |
| Mar 31, 2026 | 401,000.00 |
| Dec 31, 2025 | 438,000.00 |
| Sep 30, 2025 | 474,000.00 |
| Jun 30, 2025 | 510,000.00 |
| Mar 31, 2025 | 547,000.00 |
| Dec 31, 2024 | 583,000.00 |
| Sep 30, 2024 | 620,000.00 |
| Jun 30, 2024 | 656,000.00 |
| Mar 31, 2024 | 693,000.00 |
| Dec 31, 2023 | 729,000.00 |
| Sep 30, 2023 | 766,000.00 |
| Jun 30, 2023 | 802,000.00 |
| Mar 31, 2023 | 839,000.00 |
| Dec 31, 2022 | 875,000.00 |
| Sep 30, 2022 | 911,000.00 |
| Jun 30, 2022 | 948,000.00 |
| Mar 31, 2022 | 984,000.00 |
| Dec 31, 2021 | 1.02 Mn |
| Sep 30, 2021 | 1.06 Mn |